Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
4.055
-0.375 (-8.47%)
At close: May 12, 2025, 4:00 PM
3.951
-0.104 (-2.56%)
After-hours: May 12, 2025, 7:57 PM EDT
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 3 or 10.71% compared to the previous year.
Employees
31
Change (1Y)
3
Growth (1Y)
10.71%
Revenue / Employee
n/a
Profits / Employee
-$1,335,452
Market Cap
276.29M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CRVS News
- 3 days ago - Why Is Corvus Pharmaceuticals Stock Soaring On Friday? - Benzinga
- 3 days ago - Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 4 days ago - Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - GlobeNewsWire
- 19 days ago - Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 - GlobeNewsWire
- 4 weeks ago - Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - GlobeNewsWire
- 6 weeks ago - Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials - Seeking Alpha
- 6 weeks ago - Corvus Pharmaceuticals: Now At Cruising Altitude - Seeking Alpha